Eli Lilly and Company announced the launch of a head-to-head study to compare once-monthly injectable Emgality (galcanezumab-gnlm) with Nurtec ODT (rimegepant) for the prevention of migraine.

Pivoting from conflicting and controversial press over the company’s approved Alzheimer’s disease treatment, Biogen announced that its gene therapy drug timrepigene emparvovec failed to show a clinically meaningful benefit for a rare inherited eye disease in a Phase III trial.

AstraZeneca said a late-stage trial failed to provide evidence that the company’s Covid-19 antibody therapy protected people who had contact with an infected person from the disease, a small setback in its efforts to find alternatives to vaccines.

Sage Therapeutics’ experimental depression drug showed significant improvement in symptoms compared to placebo in a late-stage study.

Novavax

Novavax Inc. said vaccine efficacy appeared to be preserved in those receiving an approved influenza vaccine along with the company’s Covid-19 vaccine candidate compared to those receiving its Covid-19 vaccine alone.

Retinal tissue was regrown in three patients with age-related macular degeneration with geographic atrophy or dry (atrophic) AMD in a Phase I/IIa study conducted by Lineage Cell Therapeutics.

Novavax

Novavax Inc. on June 14 reported late-stage data from the company’s U.S.-based clinical trial showing its vaccine is more than 90 percent effective against Covid-19 across a variety of variants of the virus.

GSK

Britain’s GlaxoSmithKline Plc agreed to pay up to $2 billion to iTeos Therapeutics Inc. to develop and sell a potential cancer treatment together, the companies said on June 14.

Celltrion Inc. on June 14 announced positive results for the company’s experimental antibody Covid-19 treatment that the South Korean drugmaker said was safe and reduced the treatment period by nearly five days in Phase 3 global clinical trials.

Novartis

Novartis announced new Phase II data for iptacopan (LNP023), an investigational oral treatment for paroxysmal nocturnal hemoglobinuria (PNH), presented at the 26th Annual Congress of the European Hematology Association (EHA).